Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment

Journal of Clinical Oncology

Volumn 22, Issue 6, 2004, Pages 1040-1044

  Hess, Viviane ^a   A'Hern, Roger ^a   Nasiri, Nazar ^a   King, D Michael ^a   Blake, Peter R ^a   Barton, Desmond P J ^a   Shepherd, John H ^a   Ind, T ^a   Bridges, J ^a   Harrington, K ^a   Kaye, Stanley B ^a   Gore, Martin E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY; CONTROLLED STUDY; DEATH; HAZARD ASSESSMENT; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; ADULT; AGED; COLLOID CARCINOMA; DISEASE FREE SURVIVAL; FEMALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARY TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 1842509871     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.078     Document Type: Article

References (25)

1. McGuire V, Jesser CA, Whittemore AS: Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 84:399-403, 2002
2. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
3. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708, 2000
4. Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 18:106-115, 2000
5. Neijt JP, Engelholm SA, Tuxen MK, et al: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18:3084-3092, 2000
6. ICONS Collaborators: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 360:505-515, 2002
7. World Health Organization. Handbook for Reporting Results of Cancer Treatment. Publication No. 48, Geneva, Switzerland, World Health Organization, 1979
8. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
9. Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150, 1991
10. Kosary CL: FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 10:31-46, 1994
11. Makar AP, Baekelandt M, Trope CG, et al: The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56:175-180, 1995
12. Nakayama K, Takebagashi Y, Nakayama S, et al: Prognostic value of overpression of p53 in ovarian carcinoma patients receiving cisplatin. Cancer Lett 192:227-235, 2003
13. Lee KR, Scully RE: Mucinous tumors of the ovary: A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei.' Am J Surg Pathol 24:1447-1464, 2000
14. Nomura K, Aizawa S: Noninvasive, microinvasive, and invasive mucinous carcinomas of the ovary: A clinicopathologic analysis of 40 cases. Cancer 89:1541-1546, 2000
15. Watkin W, Silva EG, Gershenson DM: Mucinous carcinoma of the ovary: Pathologic prognostic factors. Cancer 69:208-212, 1992
16. Kikkawa F, Kawai M, Tamakoshi K, et al: Mucinous carcinoma of the ovary: Clinicopathologic analysis. Oncology 53:303-307, 1996
17. McBroom JW, Parker MF, Krivak TC, et al: Primary appendiceal malignancy mimicking advanced stage ovarian carcinoma: A case series. Gynecol Oncol 78:388-390, 2000
18. Sehouli J, Kopetsch OJ, Ricke J, et al: Primary mucinous adenocarcinoma of the appendix: A rare entity in the differential diagnosis of ovarian cancer. J Obstet Gynaecol Res 26:333-339, 2000
19. Fujita M, Enomoto T, Murata Y: Genetic alterations in ovarian carcinoma: With specific reference to histological subtypes. Mol Cell Endocrinol 202:97-99, 2003
20. Pieretti M, Hopenhayn-Rich C, Khattar NH, et al: Heterogeneity of ovarian cancer: Relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 20:11-23, 2002
21. Fearon E: Molecular biology of gastrointestinal cancers, in De Vita VC, Hellman S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology. Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 1044-1046
22. Tsuda H, Birrer M, Ito Y, et al: Genomic and expression analysis of microdissected ovarian clear cell adenocarcinoma using ovarian specific cDNA microarray. Proc Am Soc Clin Oncol 22:448, 2003 (abstr 1799)
23. Shimizu Y, Umezawa S, Hasumi K: A phase Il study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore 27:650-656, 1998
24. Enomoto T, Kuragaki C, Yamasaki M, et al: Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 22:447, 2003 (abstr 1797)
25. Shimizu Y, Nagata H, Kikuchi Y, et al: Cytotoxic agents active against mucinous adenocarcinoma of the ovary. Oncol Rep 5:99-101, 1998